Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John Tulinsky.
Annals of the New York Academy of Sciences | 2006
Jack W. Singer; Peter de Vries; Rama Bhatt; John Tulinsky; Peter S. Klein; Chun Li; Luka Milas; Robert A. Lewis; Sidney Wallace
Abstract: Conjugation of water‐insoluble cancer chemotherapeutic drugs to macromolecular polymers can lead to improved pharmaceutical properties and improved therapeutic ratios due to accumulation of the polymer‐drug conjugate in tumor tissue through the enhanced permeability and retention (EPR) to macromolecules associated with tumor vasculature. Pharmaceutical shortcomings of certain active camptothecins including difficulty in formulation and instability of the active lactone form due to interactions with human albumin might be improved by conjugation to polymers. In this report, conjugations of camptothecin (CPT), 10‐hydroxy‐CPT, and 9‐amino‐CPT to poly‐(l‐glutamic acid) (PG) are described; coupling was accomplished either through the 20(S)‐hydroxyl or 9 and 10 substituents with and without the use of a glycine linker. Studies using a PG paclitaxel conjugate (PG‐TXL), which is currently in Phase I testing, demonstrated that PG enhanced aqueous solubility, prolonged plasma residence time, and greatly increased the distribution of paclitaxel to tumor tissue in a murine model. In this report, we describe the use of similar conjugation technology for CPT derivatives and demonstrate that these difficult to formulate compounds can be rendered water soluble, that their maximum tolerated doses are increased, and that they retain substantial anti‐tumor activity in syngeneic and xenogeneic tumor models. Preliminary data suggest that PG with molecular weights between 37 and 50 kDa with CPT loading between 14% and 37% with or without glycine linkers display enhanced efficacy compared with nonconjugated camptothecins administered at their maximum tolerated dose.
Bioorganic & Medicinal Chemistry Letters | 1998
Cyprian O. Ogbu; Maher Qabar; P. Douglas Boatman; Jan Urban; Joseph Patrick Meara; Mark D. Ferguson; John Tulinsky; Chris Lum; Suresh Babu; Mark A. T. Blaskovich; Hiroshi Nakanishi; Fuqiang Ruan; Bolong Cao; Ryan Minarik; Thomas Little; Sherry Nelson; Minh T. Nguyen; Anna Gall; Michael Kann
The general approach of using a bicyclic template to produce inhibitors of the protease superfamily of enzymes has been investigated. The Diels-Alder cycloaddition reaction on solid support has been found to be highly efficient for the synthesis of libraries of compounds that mimic the β-strand secondary structure of proteins. Several potent and selective inhibitors of proteases have been discovered.
Archive | 2003
Rama K. Bhatt; Peter de Vries; J. Peter Klein; John Tulinsky; Robert A. Lewis; Jack Singer
Archive | 2003
Rama K. Bhatt; Baoqing Gong; Feng Hong; Scott A. Jenkins; J. Peter Klein; Cory Kohm; John Tulinsky
Archive | 2002
Rama K. Bhatt; Baoqing Gong; Feng Hong; Scott A. Jenkins; J. Peter Klein; Anil M. Kumar; John Tulinsky
Archive | 2000
Maher Qabar; Michael McMillan; Michael S. Kahn; John Tulinsky; Cyprian O. Ogbu; Jessymol Mathew
Archive | 2007
Rama K. Bhatt; Baoqing Gong; Feng Hong; Scott A. Jenkins; J. Peter Klein; Anil M. Kumar; John Tulinsky
Bioorganic & Medicinal Chemistry Letters | 2004
Baoqing Gong; Feng Hong; Cory Kohm; Scott A. Jenkins; John Tulinsky; Rama Bhatt; Peter de Vries; Jack W. Singer; Peter S. Klein
Archive | 1998
Maher Qabar; Michael McMillan; Michael S. Kahn; John Tulinsky; Cyprian O. Ogbu; Jessymol Mathew
Archive | 2009
Lynn Bonham; J. Peter Klein; Robert E. Finney; David Hollenback; Scott A. Shaffer; Norina M. Tang; Thayer White; David W. Leung; Baoqing Gong; John Tulinsky